The Effect of Intravenous Oxyhydrogen Nanobubble on Chronic Kidney Disease: Case Series
Indrajani PWMO, Hernowo AT, Ekasari CP, Yudhanata R, Sumitro SB · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 3 patients with varying stages of CKD, a 52-year-old man with CKD grade 4 and class III obesity showed a decrease in serum creatinine from 3.0 mg/dL to 2.86 mg/dL, an increase in GFR from 23 mL/min/1.73 m2 to 24.4 mL/min/1.73 m2, and improved sleep quality. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 3 patients with varying stages of CKD. A 52-year-old man with CKD grade 4 and class III obesity showed a decrease in serum creatinine from 3.0 mg/dL to 2.86 mg/dL, an increase in GFR from 23 mL/min/1.73 m2 to 24.4 mL/min/1.73 m2, and improved sleep quality.
What the Researchers Studied
The researchers studied 3 patients with varying stages of CKD.
What Effects Did Molecular Hydrogen Have?
A 52-year-old man with CKD grade 4 and class III obesity showed a decrease in serum creatinine from 3.0 mg/dL to 2.86 mg/dL, an increase in GFR from 23 mL/min/1.73 m2 to 24.4 mL/min/1.73 m2, and improved sleep quality. The authors concluded that hHOnb could be a promising complementary treatment for CKD, though larger, controlled studies are needed to confirm its efficacy and safety. Recent studies suggest that oxyhydrogen nanobubbles (HHOnb) may offer therapeutic benefits due to their antioxidative and anti-inflammatory properties.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was 3 patients with varying stages of CKD. The reported sample size was 3.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://europepmc.org/article/PPR/PPR868590.